{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:18:44Z","timestamp":1792289924076,"version":"4.4.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Advances in diagnosis and treatment have dramatically improved survival of acute immune thrombotic thrombocytopenic purpura (iTTP) and iTTP has evolved from an acute fatal condition to a chronic relapsing disorder. In addition to the risk of iTTP relapse, iTTP survivors are at risk of multiple adverse health outcomes including higher than expected rates of all-cause mortality, increased rates of stroke and other cardiovascular disease, and higher rates of morbidities such as obesity, hypertension, and autoimmune disorders. iTTP survivors also report neurocognitive impairment, depression, and reduced quality of life. Women with iTTP are at risk for recurrent iTTP, preeclampsia, and other maternal and fetal complications in subsequent pregnancies. ADAMTS13 activity during clinical remission has emerged as an important targetable risk factor for iTTP relapse and other outcomes including stroke and all-cause mortality. This review summarizes current literature regarding the epidemiology and potential mechanisms for adverse long-term sequelae of iTTP, outlines current best practices in iTTP survivorship care, and highlights a research agenda to improve long-term iTTP outcomes.<\/jats:p>","DOI":"10.3389\/fmed.2023.1137019","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T04:54:16Z","timestamp":1677560056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship"],"prefix":"10.3389","volume":"10","author":[{"given":"Sruthi","family":"Selvakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"B1","first-page":"521","article-title":"Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange.","volume":"10","author":"Rizzo","year":"2012","journal-title":"Blood Transfus."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1111\/jth.13764","article-title":"Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.","volume":"15","author":"Saha","year":"2017","journal-title":"J Thromb Haemost."},{"key":"B3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"E208","DOI":"10.1002\/ajh.24138","article-title":"Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura.","volume":"90","author":"Chaturvedi","year":"2015","journal-title":"Am J Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group.","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1160\/TH07-12-0753","article-title":"Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.","volume":"101","author":"Bresin","year":"2009","journal-title":"Thromb Haemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/asheducation-2018.1.539","article-title":"Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.","volume":"2018","author":"Dane","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.","volume":"124","author":"Hie","year":"2014","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.","volume":"125","author":"Lim","year":"2015","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.","volume":"127","author":"Page","year":"2016","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura.","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: long-term outcomes following recovery.","volume":"2018","author":"George","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/blood.2021014514","article-title":"How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge.","volume":"140","author":"Akwaa","year":"2022","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.","volume":"122","author":"Deford","year":"2013","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/ajh.26341","article-title":"Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura.","volume":"96","author":"Brodsky","year":"2021","journal-title":"Am J Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1182\/bloodadvances.2020004169","article-title":"Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission.","volume":"6","author":"Sukumar","year":"2022","journal-title":"Blood Adv."},{"key":"B19","first-page":"731","article-title":"The kidney in thrombotic thrombocytopenic purpura.","volume":"98","author":"Tsai","year":"2007","journal-title":"Minerva Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1598","DOI":"10.1097\/MD.0000000000001598","article-title":"Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura.","volume":"94","author":"Roriz","year":"2015","journal-title":"Medicine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1537-2995.2009.02101.x","article-title":"Cognitive deficits after recovery from thrombotic thrombocytopenic purpura.","volume":"49","author":"Kennedy","year":"2009","journal-title":"Transfusion."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/trf.14060","article-title":"Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura.","volume":"57","author":"Falter","year":"2017","journal-title":"Transfusion."},{"key":"B23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ajh.24060","article-title":"Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura.","volume":"90","author":"Han","year":"2015","journal-title":"Am J Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1537-2995.2008.01938.x","article-title":"Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura.","volume":"49","author":"Lewis","year":"2009","journal-title":"Transfusion."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1111\/jth.12953","article-title":"Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy.","volume":"13","author":"Vesely","year":"2015","journal-title":"J Thromb Haemost."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1182\/blood-2013-11-538900","article-title":"Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.","volume":"123","author":"Jiang","year":"2014","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura.","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.","volume":"118","author":"Scully","year":"2011","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.7326\/0003-4819-122-8-199504150-00002","article-title":"Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian apheresis group.","volume":"122","author":"Shumak","year":"1995","journal-title":"Ann Intern Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.","volume":"3","author":"Sun","year":"2019","journal-title":"Blood Adv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1537-2995.2009.02528.x","article-title":"Thrombotic thrombocytopenic purpura at the Johns Hopkins hospital from 1992 to 2008: clinical outcomes and risk factors for relapse.","volume":"50","author":"Zhan","year":"2010","journal-title":"Transfusion."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP.","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica."},{"key":"B34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ajh.25845","article-title":"Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: a multi-institutional study.","volume":"95","author":"Schieppati","year":"2020","journal-title":"Am J Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report.","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1111\/bjh.17170","article-title":"Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.","volume":"192","author":"Barba","year":"2021","journal-title":"Br J Haematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13886","article-title":"Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura.","volume":"110","author":"Comparon","year":"2022","journal-title":"Eur J Haematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/bjh.18430","article-title":"Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.","volume":"199","author":"Yin","year":"2022","journal-title":"Br J Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/bjh.12696","article-title":"Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.","volume":"164","author":"Mazepa","year":"2014","journal-title":"Br J Haematol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura.","volume":"6","author":"Berg","year":"2022","journal-title":"Blood Adv."},{"key":"B45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/jca.10053","article-title":"Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura.","volume":"18","author":"Aqui","year":"2003","journal-title":"J Clin Apher."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience.","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1182\/blood.2019000748","article-title":"Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.","volume":"134","author":"Prevel","year":"2019","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.21037\/atm.2017.03.107","article-title":"Morbidity and mortality associated with obesity.","volume":"5","author":"Abdelaal","year":"2017","journal-title":"Ann Transl Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","article-title":"Low ADAMTS13 activity is associated with an increased risk of ischemic stroke.","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1111\/jth.13479","article-title":"Low ADAMTS-13 activity and the risk of coronary heart disease \u2013 a prospective cohort study: the Rotterdam study.","volume":"14","author":"Sonneveld","year":"2016","journal-title":"J Thromb Haemost."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1161\/ATVBAHA.116.308225","article-title":"Von Willebrand factor, ADAMTS13, and the risk of mortality: the Rotterdam study.","volume":"36","author":"Sonneveld","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2141.1989.tb00226.x","article-title":"Binding of von Willebrand factor to glycoproteins Ib and IIb\/IIIa complex: affinity is related to multimeric size.","volume":"73","author":"Federici","year":"1989","journal-title":"Br J Haematol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.kint.2016.03.023","article-title":"Von Willebrand factor regulates complement on endothelial cells.","volume":"90","author":"Noone","year":"2016","journal-title":"Kidney Int."},{"key":"B54","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1055\/s-0034-1383547","article-title":"Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.","volume":"40","author":"Turner","year":"2014","journal-title":"Semin Thromb Hemost."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1161\/ATVBAHA.112.247262","article-title":"Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model.","volume":"32","author":"Jin","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood-2011-09-376202","article-title":"ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice.","volume":"119","author":"Gandhi","year":"2012","journal-title":"Blood."},{"key":"B57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejim.2020.01.024","article-title":"Prevalence of the age-related diseases in older patients with acquired thrombotic thrombocytopenic purpura.","volume":"75","author":"Agosti","year":"2020","journal-title":"Eur J Intern Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies.","volume":"67","author":"Luppino","year":"2010","journal-title":"Arch Gen Psychiatry."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/eurheartj\/eht462","article-title":"Depression and cardiovascular disease: a clinical review.","volume":"35","author":"Hare","year":"2014","journal-title":"Eur Heart J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","article-title":"Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.","volume":"373","author":"Collaboration","year":"2009","journal-title":"Lancet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2012.113905","article-title":"Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.","volume":"309","author":"Flegal","year":"2013","journal-title":"JAMA."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0156679","DOI":"10.1371\/journal.pone.0156679","article-title":"Thrombotic thrombocytopenic purpura in black people: impact of ethnicity on survival and genetic risk factors.","volume":"11","author":"Martino","year":"2016","journal-title":"PLoS One."},{"key":"B63","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004.","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e007917","DOI":"10.1161\/CIRCOUTCOMES.121.007917","article-title":"Race, racism, and cardiovascular health: applying a social determinants of health framework to racial\/ethnic disparities in cardiovascular disease.","volume":"15","author":"Javed","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s11886-022-01736-y","article-title":"Health disparities across the continuum of ASCVD risk.","volume":"24","author":"Devareddy","year":"2022","journal-title":"Curr Cardiol Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jca.10045","article-title":"A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): the six-year experience of the Oklahoma TTP-HUS study group.","volume":"18","author":"Howard","year":"2003","journal-title":"J Clin Apher."},{"key":"B67","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jca.20169","article-title":"Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry.","volume":"23","author":"George","year":"2008","journal-title":"J Clin Apher."},{"key":"B68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ajh.21881","article-title":"Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.","volume":"86","author":"Cataland","year":"2011","journal-title":"Am J Hematol."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008342","article-title":"Health following recovery from immune thrombotic thrombocytopenic purpura: the patient\u2019s perspective.","author":"Kelley","year":"2022","journal-title":"Blood Adv."},{"key":"B70","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2022-167054","article-title":"Silent cerebral infarction during immune TTP remission \u2013 prevalence, predictors and impact on cognition.","volume":"140","author":"Yu","year":"2022","journal-title":"Blood."},{"key":"B71","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/oxfordjournals.aje.a116868","article-title":"Untreated blood pressure level is inversely related to cognitive functioning: the Framingham study.","volume":"138","author":"Elias","year":"1993","journal-title":"Am J Epidemiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1023\/A:1012901124088","article-title":"Neuropsychological aspects of pediatric sickle cell disease.","volume":"11","author":"Kral","year":"2001","journal-title":"Neuropsychol Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/jpepsy\/jsz031","article-title":"Cognitive function in sickle cell disease across domains, cerebral infarct status, and the lifespan: a meta-analysis.","volume":"44","author":"Prussien","year":"2019","journal-title":"J Pediatr Psychol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(03)00305-3","article-title":"Vascular cognitive impairment.","volume":"2","author":"O\u2019Brien","year":"2003","journal-title":"Lancet Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1161\/STROKEAHA.117.017357","article-title":"Incidence of brain infarcts, cognitive change, and risk of dementia in the general population: the AGES-reykjavik study (age gene\/environment susceptibility-reykjavik study).","volume":"48","author":"Sigurdsson","year":"2017","journal-title":"Stroke."},{"key":"B76","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1161\/STROKEAHA.115.011889","article-title":"Silent brain infarction and risk of future stroke: a systematic review and meta-analysis.","volume":"47","author":"Gupta","year":"2016","journal-title":"Stroke."},{"key":"B77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.thromres.2017.01.003","article-title":"Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura.","volume":"151","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/00005792-198111000-00003","article-title":"Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature.","volume":"60","author":"Ridolfi","year":"1981","journal-title":"Medicine."},{"key":"B79","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features.","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00277-022-04936-2","article-title":"Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura.","volume":"101","author":"Brown","year":"2022","journal-title":"Ann Hematol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13023-014-0193-6","article-title":"Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case-control study.","volume":"9","author":"Ferrari","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.","volume":"124","author":"Scully","year":"2014","journal-title":"Blood."},{"key":"B83","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0301-2115(03)00199-4","article-title":"Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnancies.","volume":"111","author":"Ducloy-Bouthors","year":"2003","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2141.2010.08558.x","article-title":"ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy.","volume":"153","author":"Raman","year":"2011","journal-title":"Br J Haematol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ajh.2008.20","article-title":"Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004.","volume":"21","author":"Wallis","year":"2008","journal-title":"Am J Hypertens."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1097\/AOG.0b013e3181a45b25","article-title":"Hypertensive disorders and severe obstetric morbidity in the United States.","volume":"113","author":"Kuklina","year":"2009","journal-title":"Obstet Gynecol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/GCO.0b013e32835e0ef5","article-title":"Hypertensive disease of pregnancy and maternal mortality.","volume":"25","author":"Lo","year":"2013","journal-title":"Curr Opin Obstet Gynecol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"544.e1","DOI":"10.1016\/j.ajog.2013.08.019","article-title":"Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease.","volume":"209","author":"Lisonkova","year":"2013","journal-title":"Am J Obstet Gynecol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/ATVBAHA.111.223610","article-title":"Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology.","volume":"31","author":"Stepanian","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1179\/1607845412Y.0000000070","article-title":"Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia.","volume":"18","author":"Aref","year":"2013","journal-title":"Hematology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2004-01-0107","article-title":"Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.","volume":"104","author":"Bernardo","year":"2004","journal-title":"Blood."},{"key":"B92","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2141.2007.06688.x","article-title":"ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.","volume":"138","author":"Feys","year":"2007","journal-title":"Br J Haematol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jama.2021.8551","article-title":"Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US preventive services task force.","volume":"326","author":"Henderson","year":"2021","journal-title":"JAMA."},{"key":"B95","doi-asserted-by":"publisher","first-page":"CD004659","DOI":"10.1002\/14651858.CD004659.pub3","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications.","volume":"2019","author":"Duley","year":"2019","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1137019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T04:54:20Z","timestamp":1677560060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1137019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":95,"alternative-id":["10.3389\/fmed.2023.1137019"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1137019","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"article-number":"1137019"}}